Chlorite formulations, and methods of preparation and use thereof
Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
1. A method of administering chlorite, wherein the method comprises parenterally administering to a subject in need thereof a therapeutically effective amount of an aqueous formulation comprising an aqueous solvent, a pH adjusting agent comprising phosphate, and chlorite, wherein said chlorite is purified to greater than about 95% chlorite ions to non-chlorite ions.
2. The method of claim 1 , wherein the weight ratio of chlorite:chlorate is greater than 100:1.5.
3. The method of claim 1 , wherein the ratio of chlorite:chlorate is greater than 100:0.5.
4. The method of claim 1 , wherein the aqueous formulation is substantially free of chlorate.
5. The method of claim 1 , which the aqueous formulation substantially free of chlorine dioxide.
6. The method of claim 1 , wherein the weight ratio of chlorite:sulfate is greater than 100:16.4.
7. The method of claim 1 , wherein the weight ratio of chlorite:sulfate is greater than 100:1.6.
8. The method of claim 1 , wherein the aqueous formulation is substantially free of sulfate.
9. The method of claim 1 , wherein the weight ratio of chlorite:chloride is greater than 100:10.
10. The method of claim 1 , wherein the pH of the aqueous formulation is between about 7.0 and about 11.5.
11. The method of claim 1 , wherein the pH of the aqueous formulation is between about 7.0 and 9.
12. The method of claim 1 , wherein the pH modifying agent is a phosphate buffer.
13. The method of claim 1 , wherein the pH modifying agent is monosodium phosphate.
14. The method of claim 1 , wherein the aqueous formulation is administered intravenously.
15. The method of claim 1 , wherein the aqueous formulation is for the treatment of a neurodegenerative disorder.
16. The method of claim 15 , wherein the neurodegenerative disorder is amyotrophic lateral sclerosis (ALS).